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therapy, or in the course of other infections such as urosepsis, is the 
prime factor involved in reactivating CMV from latency, the first step 
in the pathogenesis of systemic infection. Host defense defects, in- 
duced by CMV, particularly impaired cell mediated immunity, alve- 
olar macrophage dysfunction, and neutropenia, are translated into an 
increased incidence of fungal (includmg Pneumocystis) and bacterial 
infection. Growth factors and cytokines released as a consequence 
of CMV infection upregulate the display of MHC antigens and the 
state of activation of leukocytes and vascular endothelium - the end 
result being luograft injury. There is thus a bidirectional relationship 
between CMV (and infection) and allognft injury. Finally, CMV 
infection is associated with a =- 7 fold increase in the incidence of 
post-transplant lymphoproliferative &ease. 
Resistant enterococci 
1 5129 1 Activity of Teicoplanin, Vancomycin and 8 Other 
DNgs against Gram-Positive Pathogens Isolated 
in Italy 
G.C. Schito, A. Pesce, A. Marchese, E.A. Debbia for the Italian 
Glycopeptide Resistance Group. Institute ofMhobiolo0, School .f 
Medicine, Univm'ty of Genoa, Italy 
At present only the glycopeptides teicoplanin and vancomycin re- 
rain, in most sites, a consistent activity against multi-drug resistant 
Gram-positive pathogens responsible for serious infections in the 
community and in nosocomial settings. Thus, monitoring their con- 
tinous efficacy becomes essential since the chcians are accustomed 
to use these drugs on an empirical basis. In 1995 a large multi- 
center s t u d y  enrolling 70 laboratories in 9 European countries has 
analysed 6824 Gram-positive isolates for susceptibility to the two 
glycopeptides. In Italy, besides teicoplanin and vancomycin, the in 
vim activity of several other relevant drugs was assessed by an agar 
dilution method (NCCLS) on the collection of strains (807) sent 
to this coordinating laboratory. Percent susceptible organisms at the 
breakpoints (NCCLS, 1995) are reported in the table for the antibi- 
otics tested: 
Pathogen N % Susceptible organisms to 
amp pen cef imi ncc ely nor cip tei van 
Suph. (MS) 280 32.5 100 100 95 51 75 69 100 100 
Suph. (MR) 219 80 10 14 10 99.6 100 
E . j d r  247 87 94 66 42 99.6 99.6 
E. fbrdum 46 28 43 52 17 100 9a 
This survey confirms that teicoplanin is more active than van- 
comycin on Enterococci and that it displays in practice comparable 
potency agamst the Staphylococci. In accordance with the data ob- 
tained in other countries it may be concluded that usage of the two 
glycopeptides, as occurring in Europe, may delay the appearance and 
spread of glycopeptide-resistant Gnm-positive pathogens as experi- 
enced in other regions of the world where only one molecule is 
employed. One possible mechanism for this may be ascribed to the 
fact that vancomycin can easily induce organisms carrying the V a d  
phenotype to full blown resistance while teicoplanin is devoid of this 
untoward effect. 
Glycopeptide Resistance in Enterococci: An Old 
New Resistance Mechanism 
P. Courvalin, M. Arthur, P. Reynolds. Institut Pasteur, Paris, France 
Glycopeptide resistance in enterococci is phenotypically and geno- 
typically heterogeneous. Inducible resistance to high levels of van- 
comycin and teicoplanin (VanA type) is mediated by self-transferable 
plasmids and the genes are carried by aansposon TnZ546and related 
elements. Nine polypeptides are encoded by TnZ546 that can be as- 
signed to five functional groups: transposition functions (ORFl and 
ORF2), regulation of resistance gene expression (VanR and Vans), 
synthesis of depsipeptide D-Ala-D-lactate (VanH and VanA), hydrol- 
ysis of D-Ah-D-Ah-containing peptidoglycan precursors (VanX and 
VanY) and low-level teicoplanin resistance (VanZ). The VanH de- 
hydmgenase and the VanA ligase synthesize D-Ala-D-lactate which 
replaces D-Ala-D-Ala in the peptidoglycan synthesis pathway. This 
moacation reduces the al€~mity of glycopeptides for peptidoglycan 
precursors. Strains with the VanB phenotype are inducibly resis- 
tant to various levels of vancomycin (MIC 4-1000 pg/ml), also by 
production of D-Ala-D-Lac. These strains remain susceptible to te- 
icoplanin although vancomycin induces resistance to this antibiotic. 
The compacmess and organization of the van gene clusters as well 
as the dual mechanism of resistance indicate that glycopeptide resis- 
tance is ancient. Analysis of the genes and gene order in the v a t 4  
and vanB operons and the study of the base composition within the 
clusters suggest that genes h m  merent origins have been recruited. 
Probiotic Products of Enterococci and 
Resistance 
E. Gutschik. University .f Copenhagen, Bispeljerg Hospital, Denmark 
Probiotics could be defined as non-pathogenic, host derived mi- 
croorganism which beneficially effects the host by improving micro- 
biological balance of the target niche (S.A.W Gibson). Enterocacrus 
facium (EfJ is a fast lactic acid producer and used for cheese fermen- 
tation, and fermentation of youghurt dvry products. Freeze-dried 
products of Ef has been on the market in many European countries 
as tablets or capsules with 108-109 CFU used to treat diarrhoeal 
diseases. Furthermore, same strains and preparations arevsed to treat 
diarrhoe in piglets and as dietary adjunct for newly hatched chicks 
and poults. There is a concern that vancomycin resistant enterococci 
(VRE) could emerge in human beings by simultaneous consump- 
tion of high number of enterococci and vancomycin or &om animal 
environment using probiotics of Ef. In Denmark a prodrug of Ef 
has been on the market since 1922, a yoghurt product of Ef mar- 
keted in almost all supermarkets throughout of the country, and a 
glycopeptid antibiotic; avoparcin has been used as food additive in 
animal farming for more than a decade (but banned in the spring 
of 1995). In spite of this, VRE strains almost never recognized in 
clinical specimens. Recent investigations of 65 dinically important 
isolates of enterococci (consisting 52 blood isolates) tested by PCR 
only recognized one van A positive st ra in  (MIC > 256 pg/ml) and 
one van B isolate (MIC 12 pg/ml). The global and the Scandina- 
vian experience reject any indication that the use of well-described 
and quality controlled prodrugs of Ef in humans play a signhcant 
roll for the increasing antibiotic resstance of enterococci. Theoreti- 
cally, the simultaneous use antibiotics and prodrugs of Ef as dietary 
supplementation in animals could result in selection of multiresistant 
enterococci. and should be banned. 
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Resistant Enterococci: Treatment from test 
tubes to animals to humans 
R.C. Moellering, Jr.. Harvard Medical School, Beth Ltrael Deaconecs 
Medical Center, Boston, MA, USA 
The changing patterns of antimicrobial susceptibility of enterococci 
continue to provide challenges for the microbiologist and clinician. 
In vitm testing has provided valuable assistance in the therapy of 
enterococcal mfections and animal models have been used success- 
fuuy to predict c h i d  u a t y  (or lack thereof) of in vim, obser- 
vations. In some cases, animal models have correctly predicted in 
vivo failure of compounds which exhibit in vitm activities (such as 
is true for trimethoprim/sulfamethoxizole) and in other cases they 
have provided explanations for apparent dscrepancies between in 
via0 and dtnical results (as is true for clindamycin/aminoglycoside 
combinations for intrabdominal infections). However, for the most 
part there has been a good correlation among in vitm testing, ani- 
mal model results, and clinical outcome in enterococcal infections. 
The synergistic interaction of combinations of cell-wall active agents 
and aminoglycosides has been confirmed in animal models and in 
clinical Studies as has the likehhood of failure when such combi- 
nations are used against organisms with high-level resistance to the 
aminoglycoside in the combination. Emergence of multiply-resistant 
enterococci (including vancomycin-resistant strains) is now creating 
new challenges. In vim testing and animal models are currently 
being used to discover novel treatment regimens for these multi- 
ply-resistant organisms. 
Progress in the prevention and treatment of 
chronic viral hepatitis 
The Impact of Vaccination on the Development 
and Progress of Chronic Hepatitis B 
EE. Andr6. B 
No abstract available. 
I S1341 The use of interferon and antiviral substances in 
the treatment of chronic hepatitis C 
C. Trautwein, M.P. Manns. Medizinische Hochschule, Hannover, 
-any 
Infection by the hepatitis C virus can lead to chronic hepatitis in 
more than 80% of the patients. Chronic hepatitis C infection is a 
major risk factor for the development of liver cirrhosis or hepatocel- 
lular carcinoma. Therefore therapy of chronic hepatitis C infection 
is a major goal to increase patients survival and to reduce costs which 
are associated with its complications. The only approved therapy to 
treat chronic hepatitis C infection is the admimtration of interferon 
alpha (IFN). At present 3 x 3-5 Mill IU per week are given for 
6 months. The initial response rates are hlgh (40-50%). However 
the long term response is only around 10%. Predictors of response 
for IFN treatment are the genotype of the Virus, the wal load, the 
duration of the infection until the star t  of therapy and the amino- 
mferase  level. Recent studies indicate that longer administration 
(> 18 m) of IFN may have advantages compared to the 6 months 
treatment schedule. In combination with IFN, a new nucleoside 
analogs - ribavirin - has been shown to have benefit for the ehmina- 
tion of the hepatitis C virus in chronic carriers. However only small 
numbers of patients have been treated and the promising first results 
have to be evaluated in larger series of patients. Besides the use of 
interferon and ribavirin, IL12 is now tested in phase I clinical trials. 
First results of its use in pilot studies will soon be available. 
In summary hepatitis C mfection leads to serious complications. 
However the treatment regimes presently available show only little 
benefit on the elinunation of the virus and need further improve- 
ment. 
I S135 I Molecular therapy of chronic viral hepatitis 
H.E. Blum. Department ofMedicine 11, Universiry of Frei6uq, Frei6urg, 
Germany 
The idenhfication of the molecular and genetic basis of many liver 
diseases has lead to a better understanding of their pathogenesis and 
offers new perspectives for their diagnosis, therapy and prevention. 
Genetically, liver diseases can be classified as monogenetic, com- 
plex genetic and acquired genetic diseases. Based on this classlhca- 
tion, hepatitis B virus (HEW) and hepatitis C virus (HCV) infection 
are acquired genetic diseases that can be treated by gene therapy 
aimed at blocking viral gene expression or function at Herent lev- 
els. The best studied genetic antiviral strategies are ribozymes, anti- 
sense oligonucleotides (ON) and dominant negative @N) mutants, 
all of which mhibit viral gene expression in experimental systems. 
Despite exciting recent developments, a number of problems have to 
be solved. Apart h m  their optimal design, some of the major issues 
are the specificity and stability of these therapeutic nucleic acids in 
vivo, their cellular and intracellular targeting as well as the potential 
development of resistance. Even if highly effective and target-spedc 
in vivo, ribozymes, antisense ONs and DN mutants may complement 
rather than replace existing or future therapeutic strategies, e.g., in- 
terferons, nudeoside analogues and peptide or DNA vaccines. Ther- 
apeutic DNA nccination in particular holds great promise as an 
effective molecular therapy of HBV and HCV mfection. 
I S136 ] Laboratory diagnostic parameters in the 
selection for therapy and subsequent follow-up 
of patients sufkring from chronic viral hepatitis 
E Bonino, M.R. Brunetto. Liver Pathology, Dept. of Gastroenterology, 
Molinette Hospital, Torino, Italy 
HEW and HCV are not invariably pathogenic and their genetic het- 
erogeneity could be a major cause of their pathogenetic variability. 
In clinical practice this means that presence and replication of the 
virus do not invariably imply a virus induced liver damage. Igh4 
antibodes appear the best dragnostic tools for etiologic diagnosis, 
however, they are not sensitive and specific enough for hepatitis C. 
The core protein (Sl), the envelope proteins El ,  EZ/NS1 and the 
non structural proteins NS3, NS4 and NS5 of HCV were found to 
induce antibodies against their sequential epitopes. The detection of 
all these antibodies represent and indmct evidence of ongoing HCV 
mfection. Detection of anti-HCV does not help to dlstinguish past 
&om present infections and only anti-HCV seroconversion in previ- 
ously negative patients can indicate a recent infection. In addition, a 
few patients have been shown to carry HCV-RNA in their serum 
or liver being repeatedly antibody negative. In anti-HCV negative 
infections and early acute hepatitis cases HCV-RNA detection d 
represent a valid diagnostic alternative, provided that a correct stan- 
dardization of the techniques and quantitation are performed. In 
patients undergoing antiviral therapy monitoring viremia and anti- 
body levels represent a valid tool to predict response that invariably 
has occurred in patients who had undetectable viremia and/or de- 
creasing antibody titres. 
